Brought to you by 
Ovation takes US rights to Xenazine from Prestwick
02 Oct 2008
Executive Summary
Concurrent with the announcement that it is being purchased by Biovail, neurology company Prestwick Pharmaceuticals revealed that it had granted Ovation Pharmaceuticals (CNS, hematology, and oncology) US rights to its chorea product Xenazine (tetrabenazine).
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Co-Promotion
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Ovation takes US rights to Xenazine from Prestwick
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice